Raymond James Maintains Strong Buy on CymaBay Therapeutics, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and has raised the price target from $17 to $33.
September 08, 2023 | 8:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has maintained a Strong Buy rating on CymaBay Therapeutics and raised the price target from $17 to $33, indicating a positive outlook for the company.
The Strong Buy rating maintained by Raymond James and the increase in price target from $17 to $33 indicates a positive outlook for CymaBay Therapeutics. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100